Fraser et al., 1992 - Google Patents

Fibril formation by primate, rodent, and Dutch-hemorrhagic analogs of Alzheimer amyloid. beta.-protein

Fraser et al., 1992

Document ID
7105918165452954922
Author
Fraser P
Nguyen J
Inouye H
Surewicz W
Selkoe D
Podlisny M
Kirschner D
Publication year
Publication venue
Biochemistry

External Links

Snippet

Revised Manuscript Received August 10, 1992 abstract: Deposition of extraneuronal fibrils that assemble from the 39-43 residue 3/A4 amyloid protein is one of the earliest histopathological features of Alzheimer's disease. We have used negative-stain electron …
Continue reading at pubs.acs.org (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates

Similar Documents

Publication Publication Date Title
Fraser et al. Fibril formation by primate, rodent, and Dutch-hemorrhagic analogs of Alzheimer amyloid. beta.-protein
US6462171B1 (en) Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
Hatami et al. Familial Alzheimer’s disease mutations within the amyloid precursor protein alter the aggregation and conformation of the amyloid-β peptide
Pike et al. Structure‐activity analyses of β‐amyloid peptides: contributions of the β25–35 region to aggregation and neurotoxicity
Fraser et al. α1‐Antichymotrypsin binding to Alzheimer Aβ peptides is sequence specific and induces fibril disaggregation in vitro
Fraser et al. Conformation and fibrillogenesis of Alzheimer Aβ peptides with selected substitution of charged residues
GALBETE et al. Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway
WALSH et al. In vitro studies of amyloid β-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692→ Gly) Alzheimer's disease
Sian et al. Oligomerization of β-amyloid of the Alzheimer’s and the Dutch-cerebral-haemorrhage types
Millucci et al. Conformations and biological activities of amyloid beta peptide 25-35
Salon et al. Relationship between β-amyloid degradation and the 26S proteasome in neural cells
Burdick et al. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs.
DE69621607T2 (en) CONNECTIONS WITH AGGREGATION-MODULATING EFFECT ON THE AMYLOiD PROTEIN
Carter The Interaction of Amyloid-β with ApoE: The form of beta amyloid is a partial determinant of the interaction with Apolipoprotein E
Hubin et al. Two distinct β-sheet structures in Italian-mutant amyloid-beta fibrils: a potential link to different clinical phenotypes
Di Fede et al. Good gene, bad gene: new APP variant may be both
Soto et al. Amyloid inhibitors and β-sheet breakers
El‐Agnaf et al. The influence of the central region containing residues 19− 25 on the aggregation properties and secondary structure of Alzheimer's β‐amyloid peptide
Galzitskaya New mechanism of amyloid fibril formation
Bentley et al. Apolipoprotein E structural requirements for the formation of SDS-stable complexes with β-amyloid-(1–40): the role of salt bridges
Matsunaga et al. A pH-dependent conformational transition of Aβ peptide and physicochemical properties of the conformers in the glial cell
Matsunaga et al. Conformational changes preceding amyloid-fibril formation of amyloid-beta and stefin B; parallels in pH dependence
Walsh et al. The many faces of Aβ: structures and activity
Soreghan et al. The influence of the carboxyl terminus of the Alzheimer Aβ peptide on its conformation, aggregation, and neurotoxic properties
Estrada et al. Protein misfolding disorders and rational design of antimisfolding agents